# Ovid Therapeutics (OVID) — Analyst Forecast

OVID · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/ovid/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 10 | 0 | 0 | 10 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $5.00 | $6.50 | $9.00 | 4 |

Last price $2.26 (as of Oct 16, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 15, 2026 | Wolfe Research | Initiated Coverage | Outperform | $5.00 |
| Oct 9, 2026 | Cantor Fitzgerald | Initiated Coverage | Overweight | — |
| Oct 6, 2026 | Guggenheim | Initiated Coverage | Buy | $7.00 |
| Oct 5, 2026 | Guggenheim | Initiated Coverage | Buy | $7.00 |
| Sep 11, 2026 | HC Wainwright & Co. | Maintained | Buy | $5.00 |
| Aug 3, 2026 | Oppenheimer | Maintained | Outperform | $9.00 |
| Apr 15, 2026 | Wedbush | Maintained | Outperform | $7.00 |
| Apr 9, 2026 | HC Wainwright & Co. | Maintained | Buy | $4.00 |
| Mar 26, 2026 | BTIG | Maintained | Buy | $4.00 |
| Mar 20, 2026 | Wedbush | Maintained | Outperform | $7.00 |
| Dec 22, 2025 | HC Wainwright & Co. | Maintained | Buy | $2.00 |
| Dec 22, 2025 | LifeSci Capital | Initiated Coverage | Outperform | $4.00 |
| Dec 11, 2025 | Roth Capital | Initiated Coverage | Buy | $3.00 |
| Nov 24, 2025 | HC Wainwright & Co. | Maintained | Buy | $2.00 |
| Nov 17, 2025 | Leerink Partners | Initiated Coverage | Outperform | $5.00 |
| May 27, 2025 | HC Wainwright & Co. | Maintained | Buy | $1.50 |
| Mar 24, 2025 | BTIG | Maintained | Buy | $4.00 |
| Mar 12, 2025 | Wedbush | Maintained | Outperform | $3.00 |
| Jan 29, 2025 | Oppenheimer | Upgraded | Perform → Outperform | $4.00 |
| Dec 4, 2024 | HC Wainwright & Co. | Maintained | Buy | $3.00 |

## Frequently Asked Questions

### What is the price target for OVID stock?

The average 12-month analyst price target for Ovid Therapeutics (OVID) is $6.50, with a high estimate of $9.00 and a low of $5.00, across 4 analysts.

### Is OVID a buy, sell, or hold?

Analysts covering Ovid Therapeutics currently average a Buy rating: 10 buy, 0 hold and 0 sell, from 10 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for OVID?

The average price target of $6.50 implies 187.61% upside from the last price of $2.26.

### What is the latest analyst rating on OVID?

On Oct 15, 2026, Wolfe Research initiated coverage of Ovid Therapeutics at Outperform with a price target of $5.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).